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Cells can respond to stress in various ways ranging from the activation of survival pathways to the initiation of cell death that
eventually eliminates damaged cells. Whether cells mount a protective or destructive stress response depends to a large extent on
thenatureanddurationofthestressaswellasthecelltype.Also,thereisoftentheinterplaybetweentheseresponsesthatultimately
determines the fate of the stressed cell. The mechanism by which a cell dies (i.e., apoptosis, necrosis, pyroptosis, or autophagic cell
death) depends on various exogenous factors as well as the cell’s ability to handle the stress to which it is exposed. The implications
of cellular stress responses to human physiology and diseases are manifold and will be discussed in this review in the context of
some major world health issues such as diabetes, Parkinson’s disease, myocardial infarction, and cancer.
1. Overview of Cellular Stress Responses
Cells respond to stress in a variety of ways ranging from
activation of pathways that promote survival to eliciting
programmed cell death that eliminates damaged cells. The
cell’s initial response to a stressful stimulus is geared towards
helpingthecelltodefendagainstandrecoverfromtheinsult.
However, if the noxious stimulus is unresolved, then cells
activate death signaling pathways. The fact that the cell’s
survival critically depends on the ability to mount an appro-
priate response towards environmental or intracellular stress
stimuli can explain why this reaction is highly conserved
in evolution. For example, antioxidant defence mechanisms
againstoxidativeinjuryandstressproteinssuchasheatshock
proteins occur in lower organisms as well as the mammals.
There are many diﬀerent types of stress and the response
acellmountstodealwiththeseconditionswilldependonthe
typeandleveloftheinsult.Forexample,protectiveresponses
such as the heat shock response or the unfolded protein
response mediate an increase in chaperone protein activity
which enhances the protein folding capacity of the cell, thus
counteracting the stress and promoting cell survival. The
adaptive capacity of a cell ultimately determines its fate.
Therefore, depending on the level and mode of stress,
diﬀerent defense mechanisms and prosurvival strategies are
mounted; however, if these are unsuccessful, then the cell
death programs are activated to eliminate these damaged
cells from the organism. The mechanism by which a cell
dies, that is, apoptosis, necrosis, pyroptosis, or autophagic
cell death, often depends on its ability to cope with the
conditions to which it is exposed. In this review we initially
discuss the diﬀerent forms of cell death that can be activated
by adaptive responses because activation of death signaling
pathways is the ultimate response to all types of persistent
irresolvablestress.InSection 3wewilldiscussthemanytypes
of stress a cell can encounter and the diﬀerent responses
that are activated to survive adverse conditions. Finally, we
will discuss the involvement or contribution of cellular stress
responses to disease states.
2.Stress-InducedCellDeath
Cell death has many forms and shapes. Cell death research
encompasses not only the study of programmed forms of cell
death (both apoptosis and autophagic cell death), necrosis
and other modes of cellular demise but also the role these2 International Journal of Cell Biology
phenomena play in physiological and pathological processes
including development, aging, and disease.
The cell death ﬁeld has attracted much attention in
the last two decades, mainly because of its relevance to
development, degenerative diseases, and cancer. However,
the ﬁeld of cell death research is by no means new [1]. The
concepts of cellular demise and associated terminology have
been evolving since the 19th century. The term programmed
cell death refers to controlled or regulated forms of death
associated with a series of biochemical and morphological
changes [2–4]. The realization that some forms of cell
death were biologically controlled or programmed has led
to exploitation of these processes and has made profound
impact in various ﬁelds of biology and medicine [5–7].
Nowadays, programmed cell death is synonymous with
apoptosis; however, based on the original deﬁnition it also
refers to autophagic cell death [8]. The term apoptosis was
ﬁrst used to describe a particular morphology of cell death
[9] common to the vast majority of physiological cell deaths.
This morphology includes shrinkage and blebbing of cells,
rounding and fragmentation of nuclei with condensation,
and margination of chromatin, shrinkage, and phagocyto-
sis of cell fragments without accompanying inﬂammatory
responses (in most cases) [9–11]. The morphology of cells
undergoing apoptosis appeared dissimilar and distinct from
the morphology associated with necrosis [9, 10]. Necrosis,a
term commonly used by pathologists, refers to any deaths
associated with the loss of control of ionic balance, uptake of
water, swelling, and cellular lysis [12, 13]. This lysis releases
many intracellular constituents, attracting immune cells and
provoking an inﬂammatory response.
2.1. Apoptosis. During the 1980s, apoptosis became the
focus of attention, primarily because of the relative ease
with which it could be distinguished morphologically from
other types of cell death. Within a few years apoptosis and
delineation of the underlying biochemical and molecular
pathways dominated cell death research. The discoveries of
the Bcl-2 family of proteins [14–16], death receptors [17],
caspases [18], mitochondrial cytochrome c release [19], and
a role for the endoplasmic reticulum [20]i na p o p t o s i sw e r e
just a few major milestones in the history of the ﬁeld. Today
the morphological and biochemical changes associated with
apoptosis are largely explained by activation of caspases,
and apoptosis has become generally accepted as caspase-
dependent programmed cell death [21].
Of all the forms of cell death apoptosis is the best charac-
terized and its highly regulated nature makes it an attractive
target for therapeutic intervention. Apoptosis is highly
conserved throughout evolution [22, 23] and plays a major
physiological role in both embryonic development and aging
[22, 24]. Various types of cellular stress stimuli have been
shown to trigger apoptosis, including chemotherapeutic
agents, irradiation, oxidative stress, and ER stress. Caspases,
a family of cysteine proteases, act as common death eﬀector
molecules in various forms of apoptosis [25]. Caspases are
synthesized as inactive proenzymes, which upon activation
cleave various substrates in the cytoplasm or nucleus. This
leads to many of the morphologic features of apoptotic cell
death, for example, polynucleosomal DNA fragmentation,
loss of overall cell shape, and nuclear shrinking [22, 25–27].
During apoptosis caspases are activated by diﬀerent
mechanisms. Stimulation of death receptors of the tumor
necrosis factor (TNF) receptor superfamily such as CD95
(APO-1/Fas) or TNF-related apoptosis inducing ligand
(TRAIL) receptors by their respective ligands or agonistic
antibodies results in receptor aggregation and recruitment
of the adaptor molecule Fas-associated death domain
(FADD) and procaspase-8 to form the death inducing
signaling complex (DISC) [26]. Upon recruitment caspase-8
becomes activated and initiates apoptosis by direct cleavage
of downstream eﬀector caspases [26]. The mitochondrial
pathway to caspase activation is initiated by the release from
the mitochondrial intermembrane space of apoptogenic
f a c t o r ss u c ha sc y t o c h r o m ec, apoptosis inducing factor
(AIF), second mitochondria-derived activator of caspase
(Smac)/direct IAP binding protein with low pI (DIABLO)
or Omi/high-temperature requirement protein A2 (HtrA2)
[28]. The release of cytochrome c into the cytosol results in
caspase-3 activation through formation of the cytochrome
c/Apaf-1/caspase-9-containing apoptosome complex [29].
Smac/DIABLO or Omi/HtrA2 promotes caspase activation
through neutralizing the inhibitory eﬀects of Inhibitor of
Apoptosis Proteins (IAPs) [30]. Activation of caspases has
to be tightly controlled because of the potential detrimental
eﬀects on cell survival if they are inappropriately activated.
For example, resistance to apoptosis can be caused by
aberrant function or expression of IAPs [30]. IAPs present a
group of endogenous inhibitors of caspases with eight mem-
bers in human cells, that is, XIAP, cIAP1, cIAP2, survivin,
livin (ML-IAP), NAIP, Bruce (apollon), and ILP-2 [30]. All
IAP proteins harbor one or more baculovirus IAP repeat
(BIR) domains that mediate their inhibitory interaction with
caspases [30]. Among the IAP family proteins, XIAP is the
most potent inhibitor of caspases and blocks apoptosis by
binding to active caspase-3 and -7 and by interfering with
caspase-9 activation [30].
In addition, the ratio of antiapoptotic versus pro-
apoptotic Bcl-2 family proteins regulates apoptosis sensitiv-
ity. The Bcl-2 proteins comprise both anti-apoptotic family
members, for example, Bcl-2, Bcl-XL, and Mcl-1, and pro-
apoptotic molecules such as Bax, Bak, and BH3 domain only
molecules [31]. According to the direct activation model of
Bcl-2 protein activation, BH3-only proteins that function
as direct activators (such as Bim and the cleaved form of
Bid (tBid)), directly bind to Bax and Bak to stimulate their
activation [32]. In this model, BH3-only proteins that act
as sensitizers such as Bad promote apoptosis by binding to
the prosurvival Bcl-2 proteins [32]. In contrast, the indirect
activation model proposes that BH3-only proteins activate
BaxandBakinanindirectmannerbybindingtothemultiple
anti-apoptoticBcl-2proteinsthatinhibitBaxandBak,which
inturnleadstothereleaseofBaxandBak[33,34].Moreover,
apoptosis sensitivity may be controlled by IAPs, through the
regulation of additional signaling cascades, for example, the
NF-κB, JNK, TNFR, and the ubiquitin/proteasome pathway
[30, 35]. The anti-apoptotic mechanisms regulating cellInternational Journal of Cell Biology 3
deathhavealsobeen implicated in conferring drug resistance
to tumor cells.
2.2. Autophagic Cell Death. Autophagy (self-eating) is a
multistep process that is characterized by the vesicu-
lar sequestration and degradation of long-lived cytoplas-
mic proteins and organelles, for example, mitochondria
[36]. The resulting double-membrane vesicle is termed
an autophagosome [36]. The discovery of autophagy-
related (atg) genes, ﬁrst in yeast and subsequently in
humans, has greatly enhanced the molecular understanding
of the mechanisms that are involved in the control of
autophagy [36]. The protein product of the tumor sup-
pressor gene Beclin 1 is the mammalian homolog of Atg6
and forms a multiprotein complex together with Vps34,
a class III phosphatidylinositol 3-kinase, UVRAG (UV
irradiation resistance-associated tumor suppressor gene),
and a myristylated kinase (Vps15, or p150 in humans)
[36, 37]. This complex is required for the initiation of
the formation of the autophagosome. Once this complex
forms, Vps34 becomes activated and catalyzes the generation
of phosphatidylinositol-3-phosphate, which is required for
vesicle nucleation.
Two major protein conjugation systems exist that are
required for autophagosome formation, that is, the Atg12–
Atg5 conjugation and Atg8-phosphatidylethanolamine con-
jugation systems [38]. Mechanistically, both conjugation
systems function in a manner that is closely related
to ubiquitin conjugation to proteins, with corresponding
conjugation-assisting enzymes that resemble the E1 and
E2 enzymes in ubiquitin conjugation [38]. In the Atg12–
Atg5 conjugation pathway, Atg12 is covalently conjugated
to Atg5 with the help of the E1-like enzyme Atg7 and
the E2-like enzyme Atg10 [36]. In the other conjugation
pathway, phosphatidylethanolamine (PE) is conjugated to
LC3, one of the mammalian homologues of Atg8 [36].
This process involves the sequential action of the protease
Atg4, the E1-like enzyme Atg7 and the E2-like enzyme Atg3.
Subsequently, lipid conjugation results in the conversion of
the soluble form of LC3, that is, LC3-I, to the autophagic-
vesicle-associated form that is termed LC3-II [39]. Thus,
LC3 is soluble under unstressed conditions and undergoes
association with peripheral membranes of autophagosomes
during the induction of autophagy. Via the fusion with
lysosomes,thecontentofautophagosomesisdegradedbythe
action of acid-dependent enzymes [36].
Autophagy is typically observed in cells that are exposed
to a variety of metabolic and therapeutic stresses, including
growthfactordeprivation, inhibition ofthereceptortyrosine
kinase/Akt/mammaliantargetofrapamycin(mTOR)signal-
ing, shortage of nutrients, ischemia/reperfusion, inhibition
of proteasomal degradation, the accumulation of intracel-
lular calcium, and endoplasmic reticulum (ER) stress [40–
43]. Reactive oxygen species (ROS) may provide a common
link between cellular stress signals and the initiation of
autophagy, as ROS accumulation has been reported to result
in inactivation of the cysteine protease ATG4, which in turn
causes accumulation of the ATG8-phosphoethanolamine
precursor that is required for the initiation of autophago-
some formation [44]. The functional relationship between
autophagy and cell death is complex in the sense that,
under most cellular settings, autophagy functions as a
stress adaptation that prevents cell death, whereas in some
circumstances,itconstitutesanalternativeroutetocelldeath.
This complex interrelationship between autophagy and cell
death implies that these responses are somewhat linked at
the molecular level. However, the key molecular events that
eventually determine whether autophagy is protective or
destructive are still poorly understood.
Although it is still controversial whether autophagy is
protective or toxic for the cells, accumulating evidence
suggests that it has beneﬁcial roles in the heart under
both physiological and pathological conditions [45, 46].
Autophagy was shown to mediate turnover of intracellular
proteins and organelles in the heart and protect against
hemodynamic stress [45]. Consistent with this, rapamycin,
which induces autophagy by inhibiting mTOR, can protect
myocardium against ischemia/reperfusion injury [47]. In
contrast, recent studies also demonstrated that downregu-
lation of the transcription factors, activating transcription
factor 5 or 7 (ATF5 or ATF7), using siRNA prevented
stress-induced cell death [48, 49], suggesting that the level
or timing of autophagy may be critical for deciding the
fate of the cells. Autophagic cell death has mainly been
shown during development. However, during recent years
accumulating evidences suggest that inhibition of apoptosis
induces cell death that is either associated with or dependent
on autophagy [48–50]. There is evidence of cross-talk
between apoptosis and autophagy at the molecular level,
particularly with regard to the Bcl-2 family. In addition to
its role in inhibiting apoptosis, Bcl-2 has also been shown to
inhibit autophagy [51, 52] and autophagic cell death [53].
This eﬀect is mediated through the ability of Bcl-2 to interact
with Beclin 1, a key protein in autophagosome formation
[52]. In fact, Beclin 1 has been shown to be a novel BH3-only
protein and to interact with a number of anti-apoptotic Bcl-
2 family members including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1
[54–57].
2.3. Necrosis. Necrosis has been considered as an accidental
mode of cell death for many years, implying that within a
multicellularorganismitisanunregulatedprocess.However,
there is now mounting evidence that the execution of
necrotic cell death is also regulated by a set of signaling
pathways [58–60]. For instance, death domain receptors,
for example, TNFR1, and Toll-like receptors have been
reported to trigger necrosis, in particular in the presence
of caspase inhibitors [58]. In addition, necrotic cell death
has been reported in response to cellular stress stimuli,
including ischemia or glutamate excitotoxicity in neurons or
cancercellsexposedtoalkylatingDNAdamagingagents[61–
63]. Morphologically, necrosis is characterized by a gain in
cell volume, swelling of organelles and plasma membrane
rupture, which results in the loss of intracellular contents.
Severalsignaltransductioncascadeshavebeendescribedthat
are involved in the propagation of necrotic cell death. There4 International Journal of Cell Biology
is mounting evidence that the serine/threonine kinase RIP1
is one of the key mediators of necrotic cell death, at least
in the case of death receptors or Toll-like receptors [64, 65].
Studies in RIP1-deﬁcient leukemia cells revealed that RIP1
is required for death receptor-induced necrosis [66, 67].
Furthermore, RIP1 has been described to be required for
lipopolysaccharide-induced cell death of macrophages [68].
In line with a central role of RIP1 in necrotic cell death, small
molecule inhibitors of RIP1 kinase were reported to protect
againstischaemicbraininjuryinaninvivomodelofnecrosis
[69–71]. In addition to RIP1, there is very recent evidence
that RIP3 is also critical for necrotic cell death [72–74]. To
this end, RIP3 was identiﬁed in an RNA interference screen
to be essential for necrosis in response to TNFα stimulation
and during virus infection [72, 73]. RIP3 interacts with RIP1
and regulates RIP1 phosphorylation and the generation of
ROS [72–74].
Moreover,ROSandcalciumconstituteimportantmedia-
torsthatareinvolvedinthepropagationofthenecroticsignal
in various forms of necrosis, for example, upon stimulation
with TNFα or exposure to double-stranded DNA [75, 76].
ROS may be generated intracellularly by mitochondria and
glycolysis [75, 77]. While the ER is the main intracellular
calcium store, mitochondrial calcium has been described
to stimulate oxidative phosphorylation, thereby promoting
ROS generation [78]. Both ROS and calcium can cause dam-
age to organelles and macromolecules, which contributes
to the loss of cell integrity. In addition calcium-mediated
activation of calpain can lead to cleavage and inactivation of
caspases [79], whereas the ROS can target the active site of
caspases and render them inactive [80]. Many stimuli that
drive necrosis can inhibit the apoptotic machinery.
3. Cellular StressResponses
During tissue homeostasis there is an equilibrium between
the net growth rate and the net rate of cell death [22].
Upon exposure to cellular stress this physiological home-
ostasis is in danger. Depending on the type of cellular
stress and its severity, the cell’s response can be manifold.
In essence, if the stress stimulus does not go beyond a
certain threshold, the cell can cope with it by mounting an
appropriate protective cellular response, which ensures the
cell’s survival. Conversely, the failure to activate or maintain
a protective response, for example, if the stressful agent is too
strong, results in activation of stress signaling cascades that
eventually fuel into cell death pathways [81, 82].
3.1. The Heat Shock Response. One of the main prosurvival
activities of cells, the heat shock response, was originally
described as the biochemical response of cells to mild heat
stress(i.e.,elevationsintemperatureof3–5◦Cabov enormal)
[83, 84]. It has since been recognized that many stimuli
can activate this response, including oxidative stress and
heavy metals. One of the main cellular consequences of
these stresses is protein damage leading to the aggregation
of unfolded proteins. In order to counteract this, cells
increase the expression of chaperone proteins that help in
the refolding of misfolded proteins and alleviate protein
aggregation. This confers a transient protection, leading to
a state that is known as thermotolerance, whereby cells
become more resistant to various toxic insults, including
otherwise lethal temperature elevations, oxidative stress,
various anticancer drugs, and trophic factor withdrawal [85–
88].
During initiation of the heat shock response general
protein transcription and translation is halted, presumably
to alleviate the burden of misfolded proteins in the cell.
However, transcription factors that enhance expression of
a speciﬁc subset of protective genes are selectively activated
under these conditions; these are the heat shock factors
(HSFs) [89]. Vertebrate cells have three diﬀerent HSFs:
HSF1 is essential for the heat shock response and is also
required for developmental processes, HSF2 and HSF4 are
important for diﬀerentiation and development, while HSF3
is only found in avian cells and is probably redundant with
HSF1 [90, 91]. Cells derived from mice lacking HSF1 are
sensitive to stress and are unable to develop thermotolerance
or induce heat responsive genes upon heat shock [92–94],
which has conﬁrmed that HSF1 in particular is responsible
for the heat shock response. More recent work has shown
that HSF2 can modulate HSF1-mediated expression of heat-
responsive genes [95], suggesting that HSF2 also participates
in transcriptional regulation of the heat shock response.
Inactive HSF1 is maintained in a monomeric form
in the cytoplasm through interaction with Hsp90 and
cochaperones [96, 97]( Figure 1). When the cell is exposed
to stressful conditions, there is accumulation of unfolded
proteinswhichcompetewithHSF1forHsp90binding.Thus,
HSF1 is released from the complex stimulating its transition
from a monomer to a homotrimer that can translocate to
the nucleus and bind to DNA (Figure 1). HSFs bind to
upstream sequences (heat shock elements) in the promoters
of target genes, leading to the expression of heat shock
proteins (Hsps).
Hsps are a set of evolutionary conserved proteins that
are grouped into subfamilies with molecular weights of
approximately 110, 90, 70, 60, 40, and 15–30kDa [85,
98]. Some of these, for example, Hsp90, are constitutively
expressed and act intracellularly as molecular chaperones,
preventing premature folding of nascent polypeptides [99].
Others, particularly Hsp27 and Hsp70, are usually expressed
at low basal levels and increase in response to environmental
and physiological stressors, and as such they are termed
inducible Hsps and are part of the heat shock response
[85]. Hsp27 belongs to a subfamily of stress proteins, the
small Hsps, which are detectable in virtually all organisms.
Hsp27 is also regulated by phosphorylation and dynamic
association/dissociationintomultimersrangingfromdimers
to large oligomers [100]. Hsp70 is the inducible member
of the 70kDa family of Hsps. Both Hsp27 and Hsp70 have
been shown to protect cells against the induction of cell
death by a variety of stresses and by diﬀerent modes of
cell death, including apoptosis [86, 101] and necrosis [102–
104]. They achieve these eﬀects directly, through inhibition
of cell death pathways, and indirectly, through general
prosurvival activities. For example, in their capacity asInternational Journal of Cell Biology 5
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Figure 1:Inductionofheatshockproteinsinhibitsapoptosisandpromotescellsurvival.Exposureofcellstoelevatedtemperatures,oxidative
stress,andheavymetalscausesaccumulationofunfoldedproteins,whichthroughactivationofHSF1leadstoinductionofHsp27andHsp70.
These Hsps inhibit apoptosis and promote survival.
molecular chaperones, inducible Hsps bind to and aid the
refolding of unfolded proteins, thereby preventing protein
aggregation [105]. Hsp27 can interact with actin and is thus
important for maintaining the integrity of the cytoskeleton
which may play a role in promoting survival [106].
Apart from these indirect mechanisms, Hsp27 and
Hsp70 can directly inhibit apoptosis by modulating both
the intrinsic and the extrinsic apoptosis pathways and by
interfering with caspase activation at several diﬀerent levels
[107–109]. Both Hsp27 and Hsp70 have been reported to
directly block release of pro-apoptotic factors, including
cytochrome c, from the mitochondria [110–112]. In the
cytosol, these Hsps can block apoptosome formation and
activation of downstream caspases through their ability
to bind to cytochrome c and procaspase-3 (in the case
of Hsp27) [107, 108] and procaspases -3, -7 and Apaf-
1 (in the case of Hsp70) [101, 113–115]. Hsp70 can also
interact with and inhibit apoptosis-inducing factor (AIF)
thus inhibiting apoptotic nuclear changes [116, 117]. Hsps
can also modulate the death receptor pathway. Hsp27 is
reported to inhibit DAXX, an adaptor protein that links the
Fas death receptor and the ER stress sensor IRE1 to ASK-1
and downstream JNK pro-apoptotic signaling [118]. Hsp70
also inhibits JNK activity [119–121], although this is not
observed in all systems [101]. Hsp27 and 70 can also interact
with other proteins that regulate cell survival. For example,
Hsp27 can interact with the prosurvival Ser/Thr kinase Akt
which is suggested to be important for sustained Akt activity
[122–124]. Hsp70 can exist in complex with cochaperones,
including DnaJ/Hsp40 and BAG-1 which aﬀect its ability
to modulate apoptosis [125, 126]. Overall, Hsps can be
activated or induced by a number of stresses and they
act to protect the cell by inﬂuencing a variety of cellular
processes which determine cellular fate. Hsps are, in general,
prosurvival and anti-apoptotic molecules.
3.2. The Unfolded Protein Response (UPR). Secretory and
membrane proteins undergo posttranslational processing,
including glycosylation, disulﬁde bond formation, correct
folding, and oligomerization, in the ER. In order to eﬀec-
tively produce and secrete mature proteins, cellular mech-
anisms for monitoring the ER environment are essential.
Exposure of cells to conditions such as glucose starvation,
inhibition of protein glycosylation, disturbance of Ca2+
homeostasis and oxygen deprivation causes accumulation
of unfolded proteins in the ER (ER stress) and results in
the activation of a well orchestrated set of pathways during
a phenomenon known as the unfolded protein response
(UPR) [127, 128]( Figure 2). The UPR is generally transmit-
ted through activation of ER resident proteins, most notably
inositol-requiring protein-1 (IRE1), protein kinase RNA
(PKR)-like ER kinase (PERK), and activating transcription
factor 6 (ATF6). In some cells/tissues, additional ATF6-like6 International Journal of Cell Biology
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Figure 2: ER stress and the unfolded protein response. Stress to the
ER stimulates the activation of the three endoplasmic reticulum
(ER) stress receptors, PKR-like ER kinase (PERK), activating
transcription factor 6 (ATF6) and inositol-requiring enzyme 1
(Ire1) that are involved in the unfolded protein response (UPR).
PERK phosphorylates eukaryotic initiation factor 2 (eIF2α) which
inhibits general protein translation, allowing eIF2α-independent
translation of ATF4, which activates transcription of chaperones
such as GRP78. ATF6 undergoes speciﬁc proteolysis in the Golgi
apparatus which leads to activation. One of the ATF6 target genes
is XBP1. IRE1 catalyzes the alternative splicing of XBP1 mRNA
leading to expression of the active XBP1 transcription factor.
Together the three arms of the UPR block protein translation,
increase chaperone expression and enhance ER-associated protein
degradative pathways.
bZip type transcription factors such as OASIS, CREB-H,
Tisp40, and Luman also transmit the UPR signaling [129–
132]. The UPR target genes include molecular chaperones in
the ER, folding catalysts, subunits of translocation machin-
ery (Sec61 complex), ER-associated degradation (ERAD)
molecules and anti-oxidant genes [127].
Among the UPR transmitters so far identiﬁed, IRE1 and
PERK are both type I transmembrane protein kinases which
dimerize to promote autophosphorylation and activation in
response to ER stress. Activated IRE1 endonucleolytically
cleaves mRNA that encodes a transcription factor named
homologous to ATF/CREB1 (Hac1) in yeast [133, 134]
and X-box binding protein-1 (XBP1) in higher species
[135, 136]. The spliced forms of Hac1 and/or XBP1 in
turn activate the transcription of the UPR target genes. In
contrast, activated PERK phosphorylates the α-subunit of
eukaryotic translation initiation factor-2 (eIF2α) which leads
to lower levels of eIF2 and translational suppression [137].
The PERK-eIF2α signaling pathway also activates the tran-
scription of the UPR target genes through CAP-independent
upregulationofthetranslationofatranscriptionfactorATF4
[138]. PERK can also directly phosphorylate and activate the
transcription factor, NF-E2-related factor-2 (Nrf2), which
contributes to cellular redox homeostatis by inducing the
expression of anti-oxidant genes [139, 140]. ATF6 is a type II
transmembrane protein which is cleaved by Golgi apparatus-
resident proteases site-1 protease (SP1) and site-2 protease
(SP-2) in response to ER stress [141, 142]. The cleaved N-
t e r m i n a lf r a g m e n to fA T F 6a c t sa sat r a n s c r i p t i o nf a c t o rt o
increase the transcription of the UPR target genes together
with XBP1 and ATF4.
UPR signaling generally promotes cell survival by
improving the balance between the protein load and the
folding capacity in the ER and/or by improving the secretion
of trophic factors/growth factors [143, 144]. However, if
the protein load in the ER exceeds its folding capacity, or
some defects in the UPR exist, cells tend to die, typically,
with apoptotic features (ER stress-induced cell death).
Although the exact molecular mechanisms that regulate this
type of cell death remain to be elucidated, at least three
pathways have been identiﬁed as being involved: the caspase-
12/caspase-4 pathway and CHOP and IRE1-JNK pathways.
Caspase-12 [145] in mice and caspase-4 in human [146]
have been proposed as caspases that initiate ER stress-
induced cell death. Caspase-12 null mice are reported to
be relatively resistant to ER stress and amyloid-beta toxicity
[145]. Caspase-12 is reported to directly cleave procaspase-
9 without involvement of the cytochrome c/Apaf-1 pathway
[147]. C/EBP homologous protein (CHOP), a transcription
factor that is induced downstream of PERK and ATF6
pathways,inducesERstress-inducedcelldeathatleastinpart
by suppressing the expression of Bcl-2 [148] and inducing
Bim expression [149]. IRE1 also participates in ER stress-
induced cell death by activating JNK through the binding
with ASK1 and Traf2 [150, 151].
Important roles for ER stress and ER stress-induced cell
death have also been demonstrated in a broad spectrum of
pathophysiological situations, including ischemia, diabetes,
atherosclerosis, endocrine defects, development, neurode-
generative disorders, and cancer as described below [143,
144, 152–155].
Among the UPR targets, glucose-regulated proteins
(GRPs) are the most studied and best characterized. GRPs
were originally identiﬁed as proteins induced by glucose
starvation [156]. Later, it was found that these molecules
were transcriptionally induced by ER stress through the cis-
acting element termed ER stress response element (ERSE)
[157]. GRPs include molecular chaperones in the ER such as
GRP78/Bip, GRP94, ORP150/GRP170, and oxidoreductases
in the ER such as PDI, ERp72, and GRP58/ERp57. Accu-
mulating evidence suggests that GRPs promote cell survivalInternational Journal of Cell Biology 7
when exposed to stresses such as hypoxia/ischemia [143,
158], glutamate excitotoxicity [159], and neurodegeneration
[160–162]. GRP78 could be a potential factor to inhibit
atherosclerosis by preventing ER stress-induced cell death
in endothelial cells [163]. This involves the inhibition of
the activation of SREBPs, a molecule that induces choles-
terol and triglyceride biosynthesis, or by inhibiting tissue
factor procoagulant activity [164–166]. ORP150/GRP170
was found to be associated with insulin sensitivity in both
human and mice as described below. Furthermore, GRPs
alsoplayimportantrolesinsurvivalduringearlymammalian
development [159, 167–169].
Interestingly,recentstudieshaverevealedthatsmallcom-
pounds that mimic the functions of GRPs (chemical chaper-
ones) and those that induce endogenous GRPs (molecular
chaperone inducers) can prevent protein aggregation [170],
improve protein secretion [171], and protect cells against
brain ischemia [172]o rn e u r o d e g e n e r a t i o n[ 173]. These
results suggest that the regulation of ER stress can be a novel
therapeutic target in a variety of diseases.
3.3. The DNA Damage Response. Upon cellular stress con-
ditions that are caused by exposure to chemotherapeutic
agents, irradiation, or environmental genotoxic agents such
as polycyclic hydrocarbons or ultraviolet (UV) light, damage
to DNA is a common initial event [174, 175]. DNA double
strand breaks (DSBs) and single strand breaks (SSBs) are
considered as key lesions that initiate the activation of
the DNA damage response [174]. Since the DNA duplex
is more vulnerable to chemical attack or nucleases when
it is separated into two single-stranded DNA strands, for
example, during DNA replication and transcription, SSBs
are preferentially generated under these conditions [176].
Deﬁned SSBs are also generated during distinct pathways
of DNA repair, for example, in the course of nucleotide
excision repair (NER). After DNA damage recognition,
dual incision 5  to the DNA lesion by ERCC1-XPF and
3  to the damage by XPG results in the removal of the
lesion-containing oligonucleotide [177]. DSBs are produced
directly or indirectly by many anticancer drugs, including
DNA intercalating, alkylating or crosslinking agents, topoi-
somerase inhibitors, and nucleotide analogs [174]. Once
DSBs are generated, ataxia telangiectasia mutated (ATM)
is recruited by the MRE-11-Rad50-NBS1 (MRN) complex
to sites of broken DNA and phosphorylates downstream
substrates such as checkpoint kinase 2 (Chk2) and p53
[175, 178]( Figure 3). p53 induces transcriptional activation
of diﬀerent functional programs, for example, cell cycle
regulatory proteins such as p21 and pro-apoptotic factors
such as CD95, PUMA, and BAX [179]. In addition, recent
studies have also deﬁned a nontranscriptional pro-apoptotic
activity of p53 that regulates the intrinsic mitochondria-
mediated pathway of apoptosis [180]. Damage to DNA
engages DNA repair processes to ensure the cell’s survival
in the case of sublethal damage [174]. Alternatively, if the
damage is too severe to be repaired—the DNA-damaging
insult is transmitted by the cellular stress response to the
activation of eﬀector systems to mediate cell death [174]. In
the latter case, various stress-inducible molecules, including
NF-κB, p53, JNK, or MAPK/ERK, have been implicated in
propagating and modulating the cell death signal [81, 82].
Depending on the type of lesion, DNA damage initiates
one of several mammalian DNA repair pathways, which
eventually restore the continuity of the DNA double strand.
There are two main pathways for the repair of DSBs, that
is, nonhomologous end-joining and homologous recombi-
nation [181, 182]. The former constitutes the predominant
DNA repair pathway in humans and involves DNA repair
proteins such as DNA-PK, Ku70, and Ku80 [181, 182]. Base
damage can be repaired either by enzyme-catalyzed reversal
or alternatively via excision repair [183]. Mismatch repair is
responsible for the removal of incorrectly paired nucleotides
[184]. It is important to note that DNA repair can, in princi-
ple,beerror-freeanderror-prone.Severalproteinshavebeen
discovered recently that exert a speciﬁc function in error-free
repair processes to guarantee high-ﬁdelity reconstitution of
the DNA [185]. Faithful genome transmission requires the
coordination of this highly complex network of DNA repair
pathways and repair surveillance mechanisms linked to cell
c y c l ec h e c k p o i n t sa sw e l la sc e l ld e a t hm e c h a n i s m s[ 185].
Error-prone repair or complete failure of DNA repair cannot
only lead to mutations but can also lead to the initiation of
cell death pathways [185].
3.4. The Response to Oxidative Stress. Cell survival requires
appropriate proportions of molecular oxygen and various
antioxidants. Reactive products of oxygen are amongst the
most potent and omnipresent threats faced by cells. These
include ROS such as superoxide anion (O2
•−), hydrogen
peroxide (H2O2), singlet oxygen, hydroxyl radical (OH•),
peroxy radical, as well as the second messenger nitric
oxide (NO•) which can react with O2
•− to form peroxyni-
trite (ONOO−). Normally in cells there exists equilibrium
betweenpro-oxidantspeciesandantioxidantdefensemecha-
nismssuchasROS-metabolizing enzymesincluding catalase,
glutathione peroxidase, and superoxide dismutases (SODs)
and other antioxidant proteins such as glutathione (GSH)
(Figure 4). Oxidative stress occurs when there is a distur-
banceinthispro-oxidant:antioxidantbalanceandithasbeen
implicated in several biological and pathological processes
[186]. Although most oxidative insults can be overcome by
the cell’s natural defenses, sustained perturbation of this
balance may result in either apoptotic or necrotic cell death
[186–190].
ROS can emanate from intracellular or extracellular
sources. Auto-oxidation of reduced respiratory components
of the mitochondrial electron transport chain causes the
production of free radical intermediates, O
•−
2 and H2O2,
which in the presence of iron can produce highly reactive
OH• radical via the Fenton reaction. These ROSs are dealt
with by SODs, enzymes considered to be the ﬁrst line of
defense against oxygen toxicity. ROS can also be produced
in the cytosol. For example, the arachidonic acid cascade,
yielding prostaglandins, and leukotrienes may generate ROS
when the released lipid is metabolized [191], and some
cytochrome P-450 isozymes are well-known ROS producers8 International Journal of Cell Biology
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Figure 3: DNA damage responses and cell death. Upon exposure to ionizing radiation or genotoxins, the damage to DNA is a common
initial event. DNA double strand breaks (DSBs) or single strand breaks (SSBs) are considered to be key lesions that initiate activation of
the DNA damage response. Upon DSBs, ataxia telangiectasia mutated (ATM) is recruited by the MRE-11-Rad50-NBS1 (MRN) complex to
sites of broken DNA and phosphorylates downstream substrates such as checkpoint kinase 2 (Chk2), which subsequently phosphorylates
p53. Sublethal damage to DNA can engage survival pathways via p21-mediated cell cycle arrest. Alternatively—if the damage is too severe to
be repaired—pro-apoptotic p53 target genes are activated including Bax, Puma, Noxa, and Fas, which promote apoptosis. Upon SSBs, it is
ataxia telangiectasia and Rad3 related (ATR) that gets activated and phosphorylates Chk1. Chk1 in turn phosphorylates and inhibits cdc25c
to mediated G2/M arrest or alternatively cdc25a to promote S-phase arrest.
[192]. Also, the auto-oxidation reactions of ascorbic acid,
lowmolecularweightthiols,adrenalin,andﬂavincoenzymes
can cause ROS production. In many of these cases, cytosolic
GSH neutralizes the oﬀenders. In addition to physiological
sources of ROS, diverse exogenous agents can contribute
to the intracellular production of free radicals. Most of
these compounds cause the generation of O2
•− and H2O2
[80, 193, 194]. The mechanism of action of many exogenous
agents involves redox cycling whereby an electron is accepted
to form a free radical and it is then transferred to oxygen.
Interestingly, there is evidence of cross-talk between
oxidative stress and other stress response pathways. For
example, oxidative stress is known to cause an increase
in the expression of certain inducible Hsps, particularly
Hsp27[195–197].Hspshavebeenreportedtoprotectagainst
many stresses apart from heat shock, including heavy metals,
radiation, nitric oxide, and other oxidants. In addition,
activation of the UPR stimulates upregulation of antiox-
idant genes through PERK-dependent phosphorylation of
the Nrf2 transcription factor, whose target genes includeInternational Journal of Cell Biology 9
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Figure 4: Oxidative stress and cell death. There is a plethora of
stimuli that can trigger the generation of reactive oxygen species
(ROS), among them irradiation, toxins, and also normal metabolic
processes. A range of diﬀerent ROS species have been identiﬁed,
which are kept in check by antioxidant defenses. These include
several detoxifying enzymes, for example, catalase, GSH peroxidase,
and superoxide dismutase (SOD). If these antioxidants defense
mechanisms are too weak, ROS-mediated damage to cellular
macromolecules will eventually lead to cell death.
enzymesinvolvedinGSHbiosynthesis,andhemeoxygenase-
1[ 198]. Moreover, perturbations in cellular redox status
sensitize cells to the harmful eﬀects of ER stress [199].
Similarly, accumulating evidence suggests a role for O2
•− in
the activation of autophagy [200].
ROS can cause damage to all of the major classes of
biological macromolecules, including nucleic acids, pro-
teins, carbohydrates, and lipids. When the cell’s antioxidant
defenses are overwhelmed, ROS can induce cell death.
Numerous, recent studies have shown that the mode of cell
death that occurs depends on the severity of the insult [187–
189]. In fact, oxidants and antioxidants not only determine
cell fate, but can also modulate the mode of cell death
[186, 190].
Many cytotoxic agents induce ROS, including peroxide
and O2
•−, which are involved in the induction of apoptotic
cell death [201]. H2O2 can cause the release of cytochrome
c from mitochondria into the cytosol and H2O2 may also
activate nuclear transcription factors, like NF-κB, AP-1, and
p53 [202], which may upregulate death proteins or produce
inhibitors of survival proteins. One model proposed for
H2O2 induction of apoptosis is upregulation of the Fas-FasL
system, leading to activation of caspase-8 and downstream
caspases [203, 204]. It is also possible that NO• may also
inactivate several antioxidant enzymes, including catalase,
glutathione peroxidase, and superoxide dismutases [205,
206]. Also, NO• has been reported to induce apoptosis by
increasing ceramide generation through caspase-3 activa-
tion, induction of mitochondrial permeability transition,
and activation of the Fas system [207].
Certain anti-apoptotic proteins have also been reported
to have antioxidant roles. An early suggestion regarding
the mechanism of action of Bcl-2 was that it inhibited cell
death by reducing the generation of reactive oxidants, thus
preventing critical intracellular oxidations that are requisite
forthecompletionoftheapoptoticprogram[208].However,
it is now understood that the reduction in ROS observed
with Bcl-2 overexpression is probably the result of its ability
to prevent loss of cytochrome c from mitochondria. Yet it is
interesting to note that separate studies illustrate that Bcl-2-
overexpressing cells have higher levels of total cellular GSH
[209]. The product of the baculovirus p35 gene, a potent
anti-apoptotic protein, is thought to have antioxidant role
and is protective against many apoptotic stimuli including
growthfactorwithdrawal,staurosporine,glucocorticoid,and
actinomycin-D treatment, and is a broad-spectrum caspase
inhibitor [210]. However, caspase inhibition may not be
p35’s sole mechanism of cytoprotection. Expression of the
p35 gene inhibits H2O2-induced apoptosis in insect cells and
may be acting as a sink for free radicals [211].
However, ROS are also reported to interfere with the
apoptosis death program, compelling cells to adopt an
alternative mode of cell death. Apoptotic cell death can be
switched to necrosis during oxidative stress by two possible
mechanisms: inactivation of caspases or a drop in cellular
levels of ATP levels. Caspases contain an active site cysteine
nucleophile [212] which is prone to oxidation or thiol
alkylation as well as S-nitrosylation [80, 213, 214]. This leads
to their inactivation, switching the mode of cell death to
necrosis[80,214].NO• mayactasamolecularswitchtocon-
trol protein function via reactive thiol groups. For example,
NO•-mediatedinhibitionofapoptosisinmostcasesisdueto
direct inhibition of caspase activity through S-nitrosylation
of the active site cysteine conserved in all caspases although
indirect eﬀects on caspases can also be a component of
toxicity in certain systems [214]. A switch from apoptosis to
necrosis can also occur due to a drop in cellular levels of ATP
caused by the failure of mitochondrial energy production
by oxidants [215, 216]. As mentioned previously ROS
may provide a common link between cellular stress signals
and the initiation of autophagy, and ROS accumulation
has been reported to result in inactivation of the cysteine
protease ATG4, which in turn causes accumulation of the
ATG8-phosphoethanolamine precursor that is required for
the initiation of autophagosome formation [44]. In most
circumstances, the induction of an autophagic response
serves as a strategy that should ensure the cell’s survival
[217]. Under certain conditions, however, it may also bring
about cell death, although the molecular determinants that
may control the switch from survival to death are still poorly
deﬁned. In fact, in response to several anticancer drugs ROS
can induce autophagic cell death.
4. Switch from ProsurvivalSignalingto
CellDeathSignaling
Whileconditions ofstressstimulate cellstomountprotective
responses to counteract the eﬀect of the stress on cellular
processes, if the stress remains unresolved, eventual death of
the cell ensues. This raises key questions about the molec-
ular mechanisms involved in this switch from prosurvival
signaling to prodeath signaling. For example, is there a
particular molecule that acts as a molecular switch? How do
thedurationandseverityofthestresscontributetoactivation
of this switch? As described above, in the face of exposure to10 International Journal of Cell Biology
cell stress, the cell mounts protective responses such as the
heat shock response, or the unfolded protein response, in
ordertorelievethestressandpromotesurvival.However,itis
known that if the stress is very severe or if it is prolonged, the
cell will die in spite of the activation of prosurvival signaling.
In the case of the response of cells to heat stress, the
induction of Hsps does not occur if the stress is too severe
and it has previously been suggested that the induction
of thermotolerance, that is, Hsp expression, and of cell
death is mutually exclusive events within the same cell
[87, 195]. In support of this, we have observed that in a
culture exhibiting mixed responses to a stressor, that is,
expression of Hsps, induction of apoptosis, and induction
of necrosis, the expression of Hsps was mainly observed in
the surviving cells [196]. However, a recent report suggests
that this may not always be the case, as at least one agent,
which induces expression of Hsps through direct activation
of HSF1, induces apoptosis rather than being protective
[218].
During ER stress, IRE1 may be involved in the switch
between the prosurvival UPR and initiation of cell death
pathways [219]. Interestingly, the three arms of the UPR
are thought to be activated sequentially, with PERK being
activatedmostrapidly,followedbyATF6andthenIRE1.This
suggests that time is allowed so that PERK and ATF6 may
resolve the stress, and although IRE1 also contributes to the
prosurvival UPR, it ultimately terminates it by relieving the
translational inhibition by inducing p58IPK [20]. If the stress
has been resolved, the cell returns to normal, but if not, then
apoptosis is initiated, possibly by IRE1-dependent activation
of ASK1 and its downstream target JNK. However, recently
it has been shown that attenuation of IRE1 can switch the
adaptive UPR to apoptosis and that persistent activation of
IRE1 increases cell viability upon ER stress, suggesting that
the duration of IRE1 signaling may act as a switch [219].
5. Stress Responses in Disease States
It is currently understood that a pathological stress response
isahallmarkofmanycommonhumandiseasesforanumber
of reasons. Firstly, the stress stimulus may be too strong
and/or prolonged, thereby allowing insuﬃcient time for
recovery to the normal status. Secondly, a cell’s ability to
handle even physiological levels of stress may be altered in
disease states, similarly resulting in detrimental outcomes. In
thefollowingsection,wewillprovidesomeselectedexamples
of how pathological handling of stress is one of the major
underlying causes of the pathophysiological state in very
diﬀerent types of human diseases.
5.1. Diabetes. Loss of function or death of the pancreatic β-
cells in the Islets of Langerhans in the pancreas is the major
pathological feature of diabetes mellitus. The pancreatic β-
cells have a highly developed secretory system, in which the
ER has an integral role, enabling a rapid response to glucose
stimulation by producing and releasing large amounts of
insulin. Both oxidative stress and ER stress are involved in
the failure of pancreatic β-cells and development of diabetes.
The reactive species which play an important role in
the pathogenesis of pancreatic β-cell loss in diabetes are
generated intracellularly when the β-cells are targeted by
proinﬂammatory cytokines in autoimmune Type 1 diabetes
or when exposed to a hyperglycaemic and hyperlipidaemic
milieu in Type 2 diabetes. There is evidence for the partic-
ipation of both NO• and ROS in the pathogenesis of β-cell
death in Type 1 diabetes, whereas, for β-cell dysfunction in
Type 2 diabetes, ROS are the main culprits.
Proinﬂammatory cytokines, including IL-1β (interleukin
1β), TNFα (tumor necrosis factor α), and IFNγ (interferon
γ), released from immune cells inﬁltrating the pancreas in
Type 1 diabetes, target the β-cells via their respective recep-
tors [220]. They activate a multitude of signaling cascades,
culminating in apoptosis of β-cells [221]. A number of steps
in this chain of events aﬀect the rate of generation of NO•
and ROS. It is evident from studies in patients with diabetes
andinanimalmodelsofType1diabetes,thatIL-1β isthekey
proinﬂammatory cytokine which signiﬁcantly contributes to
β-cell dysfunction and apoptosis in the pathogenesis of Type
1 diabetes. It does so through activation of the transcription
factor NF-κB which is responsible for the induction of
iNOS and subsequent production of NO• [155, 221]. The
production and release of IFNγ acts synergistically with IL-
1β. High concentrations of IFNγ are required to potentiate
the eﬀects of IL-1β on iNOS and NO• production [222].
NO• andROSseemtoalsocross-talkwithERstressandUPR
[223].
IL-1β also induces MnSOD (a manganese-dependent
SOD isoenzyme) and this results in an increased rate of
conversion of O2
•− into H2O2 in the mitochondria [224].
Cu/ZnSOD, the cytoplasmic isoenzyme, is unaﬀected by IL-
1β. The proﬁle of the eﬀects of TNFα and IFNγ alone, or in
combinationwithIL-1β,onMnSODiscomparablewiththat
of their regulation of iNOS. The eﬀects on the generation
of both radicals are not only important in themselves but
also aﬀect the balance between NO• and O2
•−, and this can
have signiﬁcant eﬀects on β-cell toxicity. A decrease in O
•−
2
through MnSOD may present as a protective signal through
a reduction of NF-κB activation and other components of
the IL-1β signaling pathway [225]. On the other hand, an
increased conversion rate of O2
•− into H2O2 b yS O Di sl i k e l y
to increase toxicity to the β-cell with its poor enzymatic
capacity for H2O2 inactivation [226, 227].
Another major proinﬂammatory cytokine, TNFα, is
released from the inﬁltrating immune cells speeds up β-
cell loss signiﬁcantly, resulting in an accelerated progression
of the disease with rapid loss of the entire pancreatic β-
cell population and Islet mass. Ceramide is likely to play a
signiﬁcant role as a mediator of O2
•− f o r m a t i o ni nT N F α-
mediated toxicity [228], thereby explaining the dominance
of ROS in the case of TNFα when compared with IL-1β.
Thus, with a signiﬁcant contribution of TNFα produced by
the inﬁltrating immune cells in Type 1 diabetes the resulting
greatercytotoxicityistheresultofthemorepronouncedROS
component of TNFα toxicity.
That the ROS-mediated component of cytokine toxicity
primarily targets the mitochondria is shown by the fact
that exposure of insulin-producing cells to IL-1β,o rt oaInternational Journal of Cell Biology 11
cytokine mixture containing both IFNγ and TNFα, causes
mitochondrial damage, while other subcellular structures
remainintact.Thisdamagecanbepreventedbyexpressionof
highlevelsofcatalaseorGSHinthemitochondria,butnotin
the cytosol [228]. IL-1β toxicity, mediated through NO• and
potentiated by IFNγ and TNFα, is likely to focus its eﬀects in
the cytoplasm. This component will presumably contribute
to ER stress, which plays a signiﬁcant role in dysfunction of
β-cells under cytokine attack [229].
β-Cell loss in Type 2 diabetes is slower than in Type 1
diabetes, typically with a long phase of β-cell dysfunction,
characterized by defective insulin secretion in response to
glucose. In Type 2 diabetes, glucolipotoxicity, rather than
proinﬂammatorycytokines,isconsideredtobeanimportant
contributing factor to β-cell dysfunction [230–234]. It is
evident from studies on β-cells exposed to a combination of
high glucose and a saturated fatty acid that NO• generation
through iNOS induction does not contribute to β-cell
dysfunction [235].
Increased mitochondrial metabolic ﬂux is required in
the β-cell for generation of the ATP signal for glucose-
induced insulin secretion [236] and its potentiation through
fatty acids [231]. On the other hand, increased metabolic
ﬂux through the respiratory chain at high glucose and lipid
concentrations should increase O2
•− formation, thereby
reducing the mitochondrial membrane potential via uncou-
pling protein 2 [230, 237]. This should decrease metabolic
ﬂux through the respiratory chain and thus reduce O2
•−
production, thereby acting in a protective manner against
ROS-induced damage, but, at the same time, attenuating
nutrient-induced insulin secretion. This casts doubt on
the concept that increased intra-mitochondrial generation
o fR O Sc r u c i a l l yc o n t r i b u t e st oβ-cell damage in Type 2
diabetes.
This interpretation is supported by the results of mor-
phological analyses showing that insulin-producing cells
exposed to the fatty acid palmitate show no signs of
mitochondrial damage, but very pronounced defects of
the ER [238], conﬁrming observations of increased ER
stress in response to glucolipotoxicity [235]. Thus one of
the prominent targets of this free-radical-mediated toxicity
might indeed be the ER.
Defects in PERK-eIF2α pathways cause Wolcott-Rallison
syndrome, a rare infantile-onset insulin-requiring diabetes
[239] and PERK-null mice developed similar phenotypes
[240].Micewithmutatedproinsulin(proinsulin-2)thatcan-
not form a disulﬁde bond (Akita mice) also develop severe
diabetes which is associated with the ER stress-induced cell
death in pancreatic β-cells [241, 242]. Mice deﬁcient for
p58IPK, which suppresses PERK-mediated phosphorylation
of eIF2α, exhibit apoptosis of pancreatic β-cells and diabetes
[243]. This suggests that the tight regulation of PERK-eIF2α
pathway is required for the maintenance of pancreatic β-
cells. In contrast, some single nucleotide polymorphisms
(SNPs) in the ORP150/GRP170 genome of Pima Indians
are associated with insulin sensitivity in peripheral tissues
[244]. Accordingly, overexpression of ORP150 enhances
insulin sensitivity and suppresses oxidative stress but does
not improve insulin secretion [245]. These ﬁndings suggest
that proper functioning of the ER is important for both
insulin synthesis in pancreatic β-cells and insulin sensitiv-
ity in peripheral tissues. Consistent with this hypothesis,
chemical chaperones such as 4-phenylbutryic acid and
tauroursodeoxycholic acid improved both insulin resistance
and insulin synthesis [171, 246].
5.2. Parkinson’s Disease. Neurodegenerative diseases are
characterized by the loss of subsets of neurons. The course
of these diseases can last decades, with the accumulation of
neuronal loss causing progressively worse symptoms. Post-
mortem tissue is usually obtained from end-stage patients, at
which time many of the evidences regarding the events pre-
ceding cell death are long gone. However, there is substantial
and growing evidence for the activation of stress responses
in neurons in all of the common neurodegenerative diseases.
This suggests that when neurons are exposed to stress, they
counteract with activation of one or more protective stress
responses; however, eventually the neurons are unable to
cope and one-by-one they are lost as the disease progresses.
There is a growing recognition that protein misfolding and
impairment of protein handling play a key role in neuronal
cell death in neurodegenerative diseases [153].
As an example of stress responses and stress-induced
cell death in neurodegenerative disease, we will describe
the evidence pertaining to Parkinson’s disease. Parkinson’s
disease is the second most common neurodegenerative dis-
ease, aﬀecting mainly people over 55 years and causing pro-
gressively worsening motor impairment. It is characterized
pathologically by the degeneration of midbrain dopaminer-
gic neurons in the substantia nigra pars compacta and the
presence of proteinaceous intracytoplasmic inclusions (Lewy
bodies) within the surviving neurons.
The molecular mechanisms that initiate dopaminergic
neuron loss in Parkinson’s disease are not known. Evidence
from various sources suggest that environmental toxins,
genetic predisposition, and aging are important factors
in the onset and progression of the disease [247–249].
Insecticides such as rotenone and the mitochondrial toxin 1-
Methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) cause
dopaminergic neuronal loss in animal models and have
been implicated in Parkinson’s disease itself [250, 251]. To
date, mutations in at least 13 PARK genes have been linked
to the pathogenesis of familial Parkinson’s disease which
include mutations in genes that encode the proteins α-
synuclein, parkin, PTEN-induced kinase 1 (PINK1), DJ-
1, leucine-rich repeat kinase2 (LRRK2), Omi/Htra2, and
ubiquitin carboxy-terminal hydrolase L1 (UCHL1) [252].
Of these, α-synuclein (along with chaperone proteins and
ubiquitin) is a major component of Lewy bodies. Parkin and
UCHL1 are linked to the ubiquitin-proteasome system that
degrades damaged or misfolded proteins [253]. In addition,
several of these genes, including parkin, PINK1, DJ-1, and
Omi/Htra2 are linked to the mitochondria and may have
roles in mitochondrial function and resistance to oxidative
stress [254].
M u t a t i o n si nP A R Kg e n e s ,a sw e l la st o x i n st h a ts p e c i f -
ically target dopaminergic neurons, have been strongly12 International Journal of Cell Biology
linked to the activation of stress responses in dopaminergic
neurons. For example, mitochondrial dysfunction due to
mutations in certain PARK genes or to environmental toxins
is linked with impairment of mitochondrial complex I which
causes oxidative stress in aﬀected cells. It has long been
known that oxidative stress is a feature of Parkinson’s disease
and it is observed in experimental models of Parkinson’s
disease and in tissues from individuals with sporadic forms
of the disease [255].
Most of the evidence regarding activation of the heat
shock response in Parkinson’s disease come from models.
Targeted overexpression of α-synuclein in mouse substan-
tia nigra causes an increase in the expression of Hsp27,
Hsp40, and Hsp70 [256, 257] and elevations in Hsp27 are
observed in in vitro models of Parkinson’s disease using
the neurotoxin 6-hydroxdopamine [196]. Recent ﬁndings
from Parkinsonian patients have described that DnaJB6 is
present in the core of Lewy bodies and is also upregulated
in astrocytes [258]. DnaJB6 is one of the Hsp40 chaperones,
which stabilizes the interactions of Hsp70s with their sub-
strate proteins. In vitro and in vivo models of Parkinson’s
disease demonstrate that overexpression of Hsps prevents
α-synuclein aggregation as well as dopaminergic neuronal
cell death due to α-synuclein and Parkinson mimetic toxins
[216, 237, 239–242]. Interestingly, the inducibility of Hsps
decreases with aging, which may contribute to the inability
of aged neurons to fully protect themselves from stresses
such as protein misfolding, aggregation, and oxidative stress
[259].
Activation of the UPR has been reported in post-
mortem brain tissue from patients with Parkinson’s dis-
ease. Speciﬁcally, phosphorylated PERK and phosphory-
lated eIF2α have been detected in dopaminergic neurons
in the substantia nigra of Parkinson’s disease patients
[260]. Phospho-PERK immunoreactivity was colocalized
with increased α-synuclein immunoreactivity in dopamin-
ergic neurons [260]. Supporting evidences from in vitro
models of Parkinson’s disease show that 6-hydroxydopamine
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPP+)
(Parkinsonmimeticdrugs)triggerERstressindopaminergic
neurons [261, 262]. Furthermore, neuronal cultures from
PERK knockout mice display an increased sensitivity to 6-
hydroxydopamine [262], while a null mutation in CHOP
results in a reduction in 6-hydroxydopamine-induced apop-
tosis in vivo [263]. However, protection was not observed
in the chronic MPTP model, despite robust expression of
CHOP [263].
The information from models, the genetic information,
aswellasanalysisofpostmortemtissue,whentakentogether,
strongly connects the induction of stress responses with the
loss of dopaminergic neurons in Parkinson’s disease. It is
likely that the induction of stress responses is the neurons
attempts at protection, which eventually fail with neuronal
cell death being the inevitable outcome. Interestingly, these
observations are mirrored in research ﬁndings of other
common neurodegenerative diseases, including Alzheimer’s
disease and Huntington’s disease, indicating the important
role for protein misfolding, aggregation and formation of
protein inclusions in these chronic diseases [153].
5.3. Myocardial Infarction. Cardiovascular disease (CVD), a
group of disorders of the heart and the vasculature, includes
high blood pressure, coronary heart disease, congestive heart
failure, stroke, and congenital heart defects. Apoptotic cell
death is a fundamental process in the morphogenesis of the
developing heart [264, 265]. Until recently the classical view
was that necrosis was the major mode of cardiomyocyte
death during CVD. However, accumulating in vitro and
in vivo studies provides compelling evidence that termi-
nally diﬀerentiated cardiomyocytes, can and do undergo
apoptosis [266]. Apoptosis has important pathophysiolog-
ical consequences, contributing to the loss and functional
abnormalities of the myocardium. Cardiomyocyte apoptosis
has been reported in a variety of cardiovascular diseases,
including myocardial infarction, end-stage heart failure,
arrhythmogenic right ventricular dysplasia, and adriamycin-
induced cardiomyopathy [267]. Animal models have been
instrumentalinestablishingtheoccurrenceofcardiomyocyte
apoptosis and in the elucidation of the apoptotic mecha-
n i s m s .F e a t u r e so fm y o c y t ea p o p t o s i sw e r eﬁ r s tr e p o r t e di n
rabbit and rat heart models of MI or ischemia/reperfusion
injury [268, 269]. Since these pioneering studies, apoptosis
has been repeatedly observed in the injured human heart
[270–274]. Due to its sporadic occurrence and the prompt
clearance of apoptotic cells by phagocytosis, apoptosis in
diseased tissue is grossly underestimated.
Oxidative damage mediated by free radicals is a con-
tributing factor to ischemia/reperfusion-induced injury in
cardiomyocytes [275–278]. Plasma and pericardial ﬂuid
obtained from patients with end stage heart failure have
increased levels of thiobarbituric acid reactive substances,
a commonly used marker of ROS production [279, 280].
Reperfusion is associated with a burst of ROS generated via
the mitochondrial respiratory chain, where partial reduction
of ubiquinone forms ubisemiquinone combine with oxygen
to form O2
•− radicals [281]. High levels of ROS can lead
to mitochondrial damage and dysfunction [282]a n dc a n
induce apoptosis in cardiac myocytes [275, 276].
In addition, enhanced levels of the heat shock response
and UPR have been demonstrated in animal models of
myocardial infarction, and overexpression of either Hsps
or GRPs enhanced tolerance against ischemia/reperfusion
injury in these models [283, 284]. Although Hsps may work
upstream of caspase-3 but downstream of cytochrome c
release [285], GRPs likely contribute to the maintenance
of intracellular Ca2+ homeostasis [284]. Similarly, overex-
pression of sarco (endo) plasmic reticulum Ca2+−ATPase
(SERCA), which regulates intracellular Ca2+ homeostasis,
improved postischemic cardiac function and decreased
myocardial infarction [286].
5.4. Cancer. Since tissue homeostasis is the result of a
subtle balance between proliferation on one side and cell
death on the other side, changes in the rate of cell death
can contribute to either the loss or gain of tissue [22].
For example, too little cell death can contribute to tumor
formation and is considered to be one of the hallmarks
of human cancers [287, 288]. Some oncogenic mutationsInternational Journal of Cell Biology 13
block cell death pathways creating a permissive environment
for genetic instability and resulting in the accumulation of
gene mutations leading to tumor initiation and progression
[289]. Also, evasion of cell death promotes resistance to
immune-based destruction, facilitates growth factor- or
hormone-independent survival, and supports anchorage-
independent survival during metastasis [288]. In addition,
defects in cell death programs may confer resistance to
cytotoxic therapies that are currently used in the clinic for
the treatment of cancer such as chemotherapy, irradiation,
or immunotherapy, since the response of cancer cells to these
treatment approaches is, to a large extent, due to their ability
to undergo cell death in response to cytotoxic stimuli [290–
292].
In principle, the signaling to apoptosis can be blocked
in cancers by loss or defective function of proapoptotic
molecules, aberrantly high expression of antiapoptotic pro-
teins, and/or by the relative dominance of cell survival
signaling pathways. For example, impaired death receptor
expression or function has been reported in a variety of
human cancers. Reduced expression of CD95 was found in
drug-resistant leukemia or neuroblastoma cells, indicating
that intact signaling via CD95 is linked to drug response
[293, 294]. CD95 mutations have been detected in both
hematological malignancies and various solid tumors [295–
300]. It is interesting to note that both agonistic TRAIL
receptors, that is, TRAIl-R1 and TRAIL-R2, are located
on chromosome 8p, a region that is frequently lost in
cancers due to heterozygosity [301, 302]. Further, a larger
range of antiapoptotic proteins are reported to be expressed
at high levels in malignant versus nonmalignant tissue,
including death domain-containing proteins that interfere
with activation of caspase-8 at the death receptor level
such as cellular FLICE-Inhibitory Protein (cFLIP) and phos-
phoprotein enriched in diabetes/phosphoprotein enriched
in astrocytes-15kDa (PED/PEA-15) [303], anti-apoptotic
Bcl-2 family proteins such as Bcl-2, Bcl-XL, and Mcl-1
[31] and IAPs, including XIAP, cIAP1, cIAP2, survivin
and livin [304]. Alternatively, apoptosis regulators with
proapoptotic functions have been reported to be lost,
mutated or epigenetically silenced in cancers. Examples
include epigenetic loss or homo- or heterozygous genomic
deletions of caspase-8 [305], single nucleotide substitution
or frameshift mutations of the bax gene in mismatch repair-
deﬁcient colon cancer or hematopoetic malignancies [306,
307], and deletion or epigenetic silencing of the bim gene
[308–310].
It is also now generally accepted that the majority of
tumors,duetopoorvascularisationofthetumormass,expe-
rience stressful conditions in the tumor microenvironment,
including low oxygen supply, nutrient deprivation, and pH
changes. These conditions activate a range of cellular stress-
response pathways, including the UPR. Recent studies have
shownthattheUPRplaysanimportantroleintumorigenesis
[311–315]. Activation of at least one branch of the UPR
h a sb e e nr e p o r t e di nan u m b e ro fc a n c e r sa n dm a n yE R
chaperones and UPR target genes show increased expression
in human tumor samples. Although activation of the UPR
has been reported in a variety of human cancers, the
role of UPR in diﬀerent forms of cancer is not yet fully
characterized.
At present it is unclear how tumor cells adapt to long-
term ER stress in vivo—whether the protective elements
of the response are enhanced, the destructive components
suppressed, or if the compromised apoptotic machinery
is suﬃcient to protect them from UPR-induced apoptosis.
Given that the UPR can trigger prosurvival and pro-
apoptotic signals, it is important to understand how modu-
lation of the UPR alters the balance between these processes
and contributes to carcinogenesis in diﬀerent cell types. The
upregulation of UPR in cancers may be beneﬁcial for the
tumor cells by increasing the protein folding capacity and
prolonging life.
Moreover, altered redox status can promote tumor
initiation and progression by blunting cell death pathways.
For example, a pro-oxidant intracellular milieu has been
linked to carcinogenesis and tumor promotion. To this
end, increased signaling via the PI3K/Akt pathway has been
shown to result in enhanced intracellular ROS generation
[316]. Similarly, cancer cells that constitutively express onco-
genic Ras have been reported to harbor higher intracellular
levels of O2
•− and to be resistant to drug-induced apoptosis
[317].
Hsps, including Hsp90, Hsp70, and Hsp27, are expressed
at increased levels in many solid tumors and haematological
malignancies. Since various oncogenic proteins that are
critically required for the malignant transformation of cells,
for example, Ras, Akt, and HER2, are client proteins of
Hsp90, elevated levels of Hsp90 favor tumor initiation
and promotion [318]. Similarly, the expression of Hsp27
and Hsp70 is abnormally high in cancers [319]. These
chaperones participate in carcinogenesis and in cell death
resistancebyblocking keyeﬀectormoleculesoftheapoptotic
machinery at the pre- and post-mitochondrial level [319].
Thus, targeting Hsps, for example, with chemical inhibitors,
is currently under investigation as anticancer strategy [318].
Error-prone repair or complete failure to repair DNA
damage as well as inherited or acquired defects in main-
tenance systems of the mammalian genome can lead to
mutations [185]. In addition, such deﬁciencies in the DNA
damage response contribute substantially to carcinogenesis
and promote the progression and treatment resistance of
cancer [185].
6.SummaryandFuturePerspectives
Cellular stress responses are an integral part of normal
physiology to either ensure the cell’s survival or alternatively
to eliminate damaged or unwanted cells. Several distinct
stress responses can be distinguished, among them the heat
shock, unfolded protein, DNA damage, and oxidative stress
responses. Despite individual signaling components, these
diﬀerent stress responses can eventually fuel into common
cell death eﬀector mechanisms, if the cell is unable to cope
with the stress. Whether or not cellular stress triggers cell
death or cell survival programs is determined by a set of
diﬀerent factors, among them the initial stress stimulus, cell14 International Journal of Cell Biology
type, and environmental factors. Because aberrant cellular
stress responses are tightly linked to many common human
diseases, a better understanding of the underlying molecular
mechanisms is expected to enable us to interfere with
these processes, for example, to switch such response from
cell death into survival programs or vice versa, depending
on the desired outcome. In addition, new insights into
the mechanistic basis of stress responses will open new
perspectives for the development of molecular targeted
treatment approaches and thus have a great potential for
drug discovery.
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